A visit guide for hidradenitis suppurativa—Managing a complex disease in a busy clinic - 15/02/21
Funding sources: None. |
|
Disclosure: Dr. Flood previously received fellowship funding from AbbVie and Janssen, paid directly to her former institution (Beth Israel Deaconess Medical Center). Dr. Porter is a consultant and investigator for Novartis, UCB, Pfizer, and Eli Lilly and an investigator for Janssen, AbbVie, and ChemoCentryx. Dr. Kimball is a consultant and investigator for AbbVie, Janssen, Lilly, Novartis, Pfizer, and UCB; a consultant for Kymera; and an investigator for ChemoCentryx; her fellowship receives funding from Janssen and AbbVie; and she was previously on the board of directors of the Hidradenitis Suppurativa Foundation. |
|
IRB approval status: Not applicable. |
|
Reprints not available from the authors. |
Vol 84 - N° 3
P. e155-e160 - mars 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?